Observation of Outcomes and Side Effects of Cesium-131 in Combination With External Beam Radiation for the Treatment of Intermediate to High Risk Prostate Cancer
Signed study-specific informed consent form prior to study entry
Intermediate Risk prostate cancer as determined by the following:
Gleason sum of 7; PSA less than 10.1 ng/ml; Stage T2a or less
Gleason sum 6 or less; PSA \>10.0 and \< 20.1ng/ml; Stage T2a or less
Gleason sum 6 or less; PSA \< 10.1; Stage T2b
High risk prostate cancer as determined by the following:
Any Gleason Sum; PSA greater than 20 ng/ml; Stage T2c or less
Gleason Sum \> 7; Any PSA; Stage T2c or less
Any Gleason Sum; Any PSA; Stage T2c
Any two or three intermediate risk factor
You may not be if
Lymph node involvement (N1)
Evidence of distant metastases (M1)
Any hormonal blockade or therapy that:
* Has persisted for more than 6 months by time of protocol screening; OR
* Is ongoing within 3 months of study enrollment
Radical surgery for carcinoma of the prostate
Prior pelvic radiation
Previous or concurrent cancers other than basal, in situ, or squamous cell skin cancers unless disease-free for ≥ 5 years
Major medical or psychiatric illness, which in the investigator's opinion, would prevent completion of treatment and would interfere with follow-up
Hip prosthesis
Inability or refusal to provide informed consent
Clareo Health | Observation of Outcomes and Side Effects of Cesium-131 in Combination With External Beam Radiation for the Treatment of Intermediate to High Risk Prostate Cancer
